Literature DB >> 12601627

Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease.

Matthew Eric Hyndman1, Braden J Manns, Floyd F Snyder, Peter J Bridge, Nairne W Scott-Douglas, Ernest Fung, Howard G Parsons.   

Abstract

The genetic and environmental factors influencing catabolism of homocysteine in end-stage renal disease (ESRD) patients remain poorly understood. This study investigated how genetic and nutritional influences affect the response to high-dose vitamin B(12) and folate treatment in ESRD patients with hyperhomocysteinemia. We studied 81 hemodialysis patients with hyperhomocysteinemia (> 16 micromol/L) on varied doses of a multivitamin containing 1 mg of folic acid per day. After screening blood work, all patients were switched to daily multivitamin therapy including 1 mg of folic acid for 4 weeks. Vitamin B(12), 1 mg/d, was added for an additional 4 weeks. Patients were then randomized to receive folic acid or placebo. The influence of the 3 methylenetetrahydrofolate reductase (MTHFR) 677 C-->T genotypes on the efficacy of vitamin therapy was assessed. In addition, we investigated how the metabolic complications of ESRD, including the relationship between methylmalonic acid (MMA) and circulating glycine, may contribute to hyperhomocysteinemia. There was no significant difference in total homocysteine (tHcy) levels between the MTHFR 677 C-->T genotypes during the screening phase of the trial. Treatment with a daily multivitamin containing 1 mg folate significantly lowered tHcy levels in all patients by 19.2%. Further supplementation with 1 mg vitamin B(12) resulted in greater tHcy reduction among subjects with the MTHFR 677 T/T genotype (P<.01, T/T v C/C or C/T) while lowering MMA equally in all MTHFR genotypes. There was a significant positive correlation between plasma glycine levels and MMA (P <.05). High-dose vitamin therapy significantly lowers, but does not normalize, MMA and tHcy levels. The MTHFR genotype, while influencing homocysteine levels, was not responsible for the majority of the elevation in plasma tHcy. Copyright 2003, Elsevier Science (USA). All rights reserved

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601627     DOI: 10.1053/meta.2003.50022

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Renal transplantation in a 14-year-old girl with vitamin B12-responsive cblA-type methylmalonic acidaemia.

Authors:  D Coman; J Huang; S McTaggart; O Sakamoto; T Ohura; J McGill; J Burke
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

2.  Folic acid supplementation and cardiac and stroke mortality among hemodialysis patients.

Authors:  June Leung; Brett Larive; Johanna Dwyer; Patricia Hibberd; Paul Jacques; William Rand
Journal:  J Ren Nutr       Date:  2010-03-19       Impact factor: 3.655

3.  Rat transcobalamin: cloning and regulation of mRNA expression.

Authors:  Seema Kalra; Shakuntla Seetharam; Raghunatha R Yammani; Bellur Seetharam
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

4.  Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis.

Authors:  Salwa Ibrahim; Ola El Dessokiy
Journal:  Clin Exp Nephrol       Date:  2009-05-26       Impact factor: 2.801

5.  Vitamin B12 supplementation in end stage renal diseases: a systematic review.

Authors:  Maryam Amini; Maryam Khosravi; Hamid Reza Baradaran; Rasha Atlasi
Journal:  Med J Islam Repub Iran       Date:  2015-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.